Regulatory requirements of EU MCQs With Answer

Regulatory requirements of EU MCQs With Answer is designed to help M. Pharm students master the fundamentals and finer points of European Union (EU) pharmaceutical regulation under Regulatory Affairs (MPH 104T). This quiz-style blog covers critical EU frameworks such as authorization routes (centralised, decentralised, mutual recognition, national), data/market protection, variations, pharmacovigilance (QPPV, PSMF, EudraVigilance), GMP/QP certification, clinical trial regulation (CTR 536/2014), risk management, orphan and pediatric incentives, labeling and safety features, and key coordinating bodies like EMA, PRAC, and CMDh. Each question aims to reinforce compliance-oriented thinking and exam readiness by focusing on what regulators expect in real submissions and lifecycle management across the EU/EEA.

Q1. Which EU marketing authorization route is mandatory for most biotechnology products, advanced therapy medicinal products (ATMPs), and orphan medicines?

• The Centralised Procedure
• The Decentralised Procedure
• The Mutual Recognition Procedure
• The purely National Procedure

Correct Answer: The Centralised Procedure

Q2. What is the standard CHMP evaluation time (active assessment days) for a centralised marketing authorization application?

• 210 days
• 150 days
• 90 days
• 300 days

Correct Answer: 210 days

Q3. In the EU, the Decentralised Procedure (DCP) is most appropriate when:

• The product has no marketing authorization in any EU Member State
• The product already has a marketing authorization in one EU Member State
• The product can only be assessed centrally by EMA
• The product is limited to one Member State indefinitely

Correct Answer: The product has no marketing authorization in any EU Member State

Q4. Which statement best describes the EU data and market protection framework for new active substances?

• 8 years data exclusivity + 2 years market protection + 1 additional year for a significant new indication
• 5 years data exclusivity + 5 years market protection
• 10 years market protection only
• 3 years for all products regardless of novelty

Correct Answer: 8 years data exclusivity + 2 years market protection + 1 additional year for a significant new indication

Q5. Which EU variation type generally requires prior approval before implementation?

• Type IA
• Type IAIN
• Type IB
• Type II

Correct Answer: Type II

Q6. Under EU pharmacovigilance legislation, the Qualified Person responsible for Pharmacovigilance (QPPV) must:

• Reside and operate in the EU/EEA with continuous availability
• Be located anywhere globally if reachable by email
• Be a physician only, regardless of residence
• Report solely to PRAC with no company role

Correct Answer: Reside and operate in the EU/EEA with continuous availability

Q7. Where must the Pharmacovigilance System Master File (PSMF) be located as per EU requirements?

• Within the EEA at the QPPV site or main pharmacovigilance site specified in the MA dossier
• At company global HQ, regardless of location
• At EMA’s offices
• With the company’s CRO anywhere in the world

Correct Answer: Within the EEA at the QPPV site or main pharmacovigilance site specified in the MA dossier

Q8. What are the standard EU ICSR reporting timelines to EudraVigilance for marketed products?

• Serious within 7 days; non-serious within 15 days
• Serious within 15 days; non-serious within 90 days
• Serious within 30 days; non-serious within 60 days
• Serious and non-serious both within 15 days

Correct Answer: Serious within 15 days; non-serious within 90 days

Q9. For the EU Package Leaflet (PL), which requirement ensures patient comprehension?

• Mandatory QR code linking to the SmPC
• User/Readability testing with target patient groups
• Regulator-authored content only
• Use of Latin-only medical terminology

Correct Answer: User/Readability testing with target patient groups

Q10. Under the EU Falsified Medicines Directive and Delegated Regulation, most prescription medicines must bear:

• A tamper-proof hologram only
• A unique identifier in a 2D DataMatrix and an anti-tampering device
• An RFID chip embedded in blisters
• No additional features beyond batch and expiry

Correct Answer: A unique identifier in a 2D DataMatrix and an anti-tampering device

Q11. The EU orphan designation prevalence threshold is defined as a condition affecting:

• Fewer than 1 in 100,000 people in the EU
• Fewer than 5 in 10,000 people in the EU
• Fewer than 10 in 10,000 people in the EU
• Fewer than 50,000 people in the EU

Correct Answer: Fewer than 5 in 10,000 people in the EU

Q12. For non-orphan medicines, completion of an agreed PIP (or waiver/deferral as applicable) typically grants which reward?

• Two years of market exclusivity
• Six-month extension of the Supplementary Protection Certificate (SPC)
• Ten-year data exclusivity
• Priority review in all Member States

Correct Answer: Six-month extension of the Supplementary Protection Certificate (SPC)

Q13. In the EU, who certifies each batch before release to market or after importation?

• Qualified Person (QP)
• Chief Medical Officer (CMO)
• Regulatory Affairs Manager
• Quality Control Analyst

Correct Answer: Qualified Person (QP)

Q14. What is the EU “sunset clause” for marketing authorizations?

• MA lapses if the MAH changes within one year
• MA lapses if the product is not marketed for three consecutive years
• MA lapses if PSURs are not submitted for two years
• MA lapses if the SmPC is not updated annually

Correct Answer: MA lapses if the product is not marketed for three consecutive years

Q15. Which legislation established the single EU portal and database (CTIS) for clinical trials?

• Directive 2001/20/EC
• Regulation (EU) No 536/2014
• Regulation (EC) No 726/2004
• Directive 2001/83/EC

Correct Answer: Regulation (EU) No 536/2014

Q16. In the EU, a Risk Management Plan (RMP) is:

• Optional for new MAAs unless the product is biological
• Required for all new MAAs and certain significant variations
• Submitted only upon PRAC request
• Applicable to vaccines only

Correct Answer: Required for all new MAAs and certain significant variations

Q17. Which body coordinates Decentralised and Mutual Recognition Procedures among EU/EEA Member States?

• CHMP
• PRAC
• CMDh
• CAT

Correct Answer: CMDh

Q18. In EU submissions, what is the primary purpose of the QRD templates?

• To calculate bioequivalence sample size
• To harmonize SmPC, PL, and labeling format and phrasing across EU languages
• To validate electronic signatures in eCTD
• To generate barcode content for cartons

Correct Answer: To harmonize SmPC, PL, and labeling format and phrasing across EU languages

Q19. What is “worksharing” in the context of EU variations?

• A procedure to share clinical data between MAHs
• A single assessment of the same variation across multiple MAs/Member States
• Transfer of MAH responsibilities to a third party
• A joint procurement mechanism for APIs

Correct Answer: A single assessment of the same variation across multiple MAs/Member States

Q20. A Certificate of Suitability (CEP) issued by EDQM demonstrates:

• Compliance of the API with the relevant Ph. Eur. monograph
• Authorization to market the finished product in the EU
• Approval of the clinical trial protocol
• Exemption from GMP inspections

Correct Answer: Compliance of the API with the relevant Ph. Eur. monograph

Download